Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106069467v1
21/4/400    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rettenbacher, M. A.
Right arrow Articles by Wolfgang Fleischhacker, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rettenbacher, M. A.
Right arrow Articles by Wolfgang Fleischhacker, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on June 1, 2007
Journal of Psychopharmacology, Vol. 21, No. 4, 400-404 (2007)
DOI: 10.1177/0269881106069467
© 2007 British Association for Psychopharmacology

Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study

Maria A. Rettenbacher

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria, maria.rettenbacher{at}uibk.ac.at

Martina Hummer

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

ALex Hofer

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

Susanne Baumgartner

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

Christoph Ebenbichler

Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria

Monika EdLinger

Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

Georg Kemmler

Department of General Psychiatry, Medical University Innsbruck, Austria

Monika Lechleitner

Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria

W. Wolfgang Fleischhacker

Deptartment of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria

Although second-generation antipsychotics have notabLe benefits as compared to typical antipsychotics, their use has been associated with metaboLic disturbances, such as alterations of glucose homeostasis. It is still being debated whether this is a class effect of second-generation antipsychotics.

We conducted a prospective, open study comparing body weight, parameters of insuLin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisuLpride ( n = 12). All parameters were assessed monthly over a period of 12 to 16 weeks. Body mass index (BMI), fasting serum insulin Levels and the Homeostasis Model Assessment (HOMA) index for insulin resistance increased significantly in patients treated with clozapine. None of these parameters increased significantly in patients treated with amisulpride.

This study indicates that treatment with clozapine appears to have a higher risk to Lead to metabolic disturbances than amisupride.

Key Words: antipsychotics • insulin • weight • glucose metabolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?